Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Hoffmann-La Roche
Ralf Gutzmer; Daniil Stroyakovskiy; Helen Gogas; Caroline Robert; Karl Lewis; Svetlana Protsenko; Rodrigo P Pereira; Thomas Eigentler; Piotr Rutkowski; Lev Demidov; Georgy Moiseevich Manikhas; Yibing Yan; Kuan-Chieh Huang; Anne Uyei; Virginia McNally; Grant A McArthur; Paolo A Ascierto